Enzon, Inc.

Other

Cornerstone Pharmaceuticals, Inc.

Rafael Pharmaceuticals, Inc.

At Biochem

United Therapeutics Corporation

The United States of America As Represented by the Department of Health

Pre-d Partners LLC

Biodev, LLC

Shorr, Robert

Rodriguez, Robert

Boteju, Lakmal

Marecek, James

Bingham, Paul

Kwok, Thomas

Robert G Shorr

Robert J Rodriguez

Mike A Clark

David R Filpula

Marc D Whitlow

John S Bomalaski

Carl W Gilbert

Maoliang Wang

Thomas Kwok

Paul M Bingham

Kwang Nho

Lakmal Boteju

Lihsyng Standford Lee

James Marecek

Myung-ok P Cho

Richard B Greenwald

Michael Clark

Martine A Rothblatt

Brian M Martin

Edward J Ginns

Myung-Ok Cho

Tikam Jain

Alahari Arunakumari

Michael David Bentley

Xuan Zhao

Robert A Rodriguez

Christopher J Molineaux

Chyi Lee

David H Goddard

Jeffrey Schwartz

Nahla Mensi-Fattohi

Hariharan Shankar

Barbara Czuba

Robert Rodriguez

Compositions for the treatment, prevention of, proliferation of, or killing of cells associated with metastatic progression of cancer in a cancer patient are disclosed. More specifically, compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed. Compositions disclosed herein include formulations of monolaurin, and formulations including monolaurin and additional components. Also, methods of treating metastatic cancer and/or preventing cancer relapse in a cancer patient by administering compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed. The compositions and methods disclosed herein are useful for killing circulating cancer cells that cause metastasis and cancer relapse.

Compositions for the treatment of metastatic cancer

The disclosure provides thiol-containing alkyl fatty acid compound formulations for intravenous, parenteral or oral administration. The compositions of the present technology have optimal controlled bioavailability and are useful for treating metabolic dysfunctions such as pre-diabetes, Metabolic Syndrome and diabetes. Also provided are methods of treatment comprising the daily administration of the disclosed thiol-containing alkyl fatty acid formulations.

Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome

Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.

Pharmaceutical compounds

Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.

Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells

The present invention is directed to a pharmaceutical composition containing a cancer-treating effective amount of a class of prostacyclin derivatives, and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of cancer.

Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer

The present invention relates to single-chain antigen-binding molecules capable of glycosylation. Compositions of, genetic constructions coding for, and methods for producing monovalent and multivalent single-chain antigen-binding molecules capable of glycosylation are described and claimed. Composition of, genetic constructions coding for, and methods for producing glycosylated monovalent and multivalent single-chain antigen-binding molecules capable of polyalkylene oxide conjugation are described and claimed. The invention also relates to methods for producing a polypeptide having increased glycosylation and the polypeptide produced by the described method. Uses resulting from the multifunctionality of a glycosylated/polyalkylene oxide conjugated antigen-binding protein are also described and claimed.

Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof

Prostaglandin and analogs thereof which include protective groups attached to at least one site which are pharmaceutically acceptable and which are capable of slowing the metabolic rate of the active groups for administration to a warm blooded animal for the treatment of congestive heart failure.

Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure

A method for rendering water-insoluble materials water-soluble is provided. The method is useful for solubilizing substantially water-insoluble bioactive materials such as drugs. This is accomplished by forming a non-covalently bonded complex between the drug and a polymer which is soluble in both water and an organic solvent. This is carried out by combining the desired medicinal agent with the polymer is an organic solvent, removing the solvent and dissolving the complex in water or aqueous buffer. When the organic solvent is evaporated, a solid complex is recovered which is water-soluble. Methods of treatment with the complexes are also provided.

Alkyl or olefinic endcapped polyalkylene oxide solubilizer

A method of reducing side-effects associated with administering oxygen-carrying proteins to mammals is disclosed. The method includes:

Method of reducing side effects associated with administration of

Growing community of inventors

Edison, NJ, United States of America

Robert G Shorr